BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 124800
Published online Nov 27, 2026. doi: 10.4254/wjh.124800
Molecular pathophysiology of hepatocellular carcinoma: Role of tumor microenvironment and vascular signaling
Deepti Sharma, Babu Lal Meena, Vanya Garg
Deepti Sharma, Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Babu Lal Meena, Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Vanya Garg, Department of Molecular and Cellular Medicines, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Author contributions: Sharma D, Meena BL contributed to concept, design and writing of article; Garg V contributed to concept, design and writing of article; all authors approved the manuscript and its submission to the journal.
AI contribution statement: The authors declare that no AI tools were used in the development or writing of this manuscript and take full responsibility for its integrity, accuracy, and originality.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Deepti Sharma, MD, Additional Professor, Department of Radiation Oncology, Institute of Liver and Biliary Sciences, Vasant Kunj, New Delhi 110070, India. drdeeptisharma16@gmail.com
Received: June 24, 2026
Revised: August 1, 2026
Accepted: October 10, 2026
Published online: November 27, 2026
Processing time: 148 Days and 21.7 Hours
Abstract

Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancers and remains a top three cause of cancer-related mortality worldwide, with an estimated 900000 new cases and 830000 deaths annually. Despite advances demonstrated in recent phase III trials, median overall survival (OS) among patients with unresectable HCC treated with first-line immunotherapy and antiangiogenic combinations remains approximately 15-20 months, underscoring the biological aggressiveness of the disease. The molecular pathophysiology of HCC is shaped not only by recurrent genomic alterations including TP53, TERT promoter, CTNNB1, and chromatin-modifying genes but also by a chronically inflamed, fibrotic tumor microenvironment (TME) in which nuclear factor kappa-B, Janus kinase/signal transducer and activator of transcription, and transforming growth factor (TGF)-β signaling intersect with profound vascular remodeling. Aberrant angiogenesis represents a central hallmark of HCC. Immunohistochemical analyses demonstrate vascular endothelial growth factor (VEGF) positivity in approximately 65%-70% of tumors, with VEGF-expressing HCCs exhibiting significantly higher rates of capsular infiltration, microvascular invasion, intrahepatic metastasis, and inferior OS, with reported hazard ratios for death of approximately 1.5-2.0. In parallel, accumulation of hypoxia-inducible factor (HIF)-1α and HIF-2α in hypoxic tumors and following locoregional therapies (e.g., transarterial chemoembolization and radiofrequency ablation) transcriptionally activates VEGFA, ANGPT2, CXCL12, and glycolytic programs, driving neo-angiogenesis, vascular tortuosity, and metabolic reprogramming. Concurrent upregulation of MET, AXL, and fibroblast growth factor receptor signaling within tumor and stromal compartments further promotes invasion, epithelial-mesenchymal transition, and resistance to VEGF-targeted tyrosine kinase inhibitors. Non-parenchymal cells often constituting ≥ 50% of the tumor mass including liver sinusoidal endothelial cells, activated hepatic stellate cells, cancer-associated fibroblasts, and tumor-associated macrophages, secrete VEGF, ANGPT2, interleukin-6, CCL2, CXCL8, and TGF-β, reinforcing vascular abnormalization and T-cell exclusion. These molecular circuits are directly leveraged in contemporary clinical trials. In IMbrave150, atezolizumab plus bevacizumab achieved a median OS of 19.2 months vs 13.4 months with sorafenib (hazard ratio 0.66), with 12-month OS rates of approximately 67% vs 55% and objective response rates of 27% vs 12% by RECIST 1.1. In HIMALAYA, the STRIDE regimen (tremelimumab plus durvalumab) produced a median OS of 16.4 months compared with 13.8 months for sorafenib (hazard ratio 0.78), with 36-month OS rates near 30% vs 20%, respectively. Exploratory analyses from these and related studies indicate that angiogenic, hypoxia-related, interferon-γ, and WNT/β-catenin gene signatures stratify clinical benefit and illuminate mechanisms of primary resistance to immune–antiangiogenic therapy. This review integrates molecular, TME-level, and clinical trial data to define biomarker-aligned, mechanism-based vascular and immune targeting strategies aimed at achieving more durable disease control in advanced HCC.

Keywords: Hepatocellular carcinoma; Tumor microenvironment; Vascular endothelial growth factor; Hypoxia-inducible factors; Immune checkpoint inhibitors

Core Tip: Hepatocellular carcinoma (HCC) progression is governed by dynamic interactions between tumor genomics, stromal elements, hypoxia, and aberrant vascular signaling. The success of immune-antiangiogenic combinations validates the concept that vascular normalization and immune reprogramming are biologically interconnected processes. This review integrates molecular, tumor microenvironment-level, and clinical trial data to define biomarker-aligned, mechanism-based vascular and immune targeting strategies aimed at achieving more durable disease control in advanced HCC.

Write to the Help Desk